In the BioHarmony Drug Report Database

"Preview" Icon

Thalidomide

Thalomid, Thalidomide Celgene, Thalidomide Pharmion (thalidomide) is a small molecule pharmaceutical. Thalidomide was first approved as Thalomid on 1998-07-16. It is used to treat aphthous stomatitis, behcet syndrome, crohn disease, discoid lupus erythematosus, and erythema multiforme amongst others in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target protein cereblon. Thalomid’s patent is valid until 2023-12-09 (FDA).

 

Trade Name

 

Thalidomide Celgene, Thalidomide Pharmion
 

Common Name

 

thalidomide
 

ChEMBL ID

 

CHEMBL468
 

Indication

 

aphthous stomatitis, behcet syndrome, crohn disease, discoid lupus erythematosus, erythema multiforme, erythema nodosum, graft vs host disease, langerhans-cell histiocytosis, leprosy, multiple myeloma, renal cell carcinoma, rheumatoid arthritis, waldenstrom macroglobulinemia
 

Drug Class

 

Thalidomide derivatives

Image (chem structure or protein)

Thalidomide structure rendering